Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

Pure R3t@trutide

R 1,299.00

Pure R3t@trutide 10mg: Pure R3t@trutide 20mg

Pure R3t@trutide 30 mg is a research-grade synthetic peptide supplied as a lyophilised powder for laboratory and scientific research applications.

R3t@trutide, also known as Retatrutide, is an experimental triple receptor agonist investigated for its activity at the GIP, GLP-1 and glucagon receptors. Research focuses on these interconnected signalling pathways and their relationship to metabolic regulation, glucose metabolism, energy balance and appetite-related biology.

This 30 mg research presentation is supplied with PURE Labs' stated 99% purity and third-party verification.

Each qualifying product includes 3ml of 0.9% Benzyl Alcohol Bacteriostatic Water.

For laboratory and scientific research use only. Not intended for human or veterinary use, consumption, diagnosis, treatment, or prevention of disease.

Key Features

• Research Grade • 30mg reference strength • 99% Purity • Third-Party Verified • Lyophilised peptide • GIP / GLP-1 / glucagon triple receptor agonist • Laboratory research use

Dosage & Usage

CAS: 2381089-83-2
Formula: C222H342N50O65
Molecular Weight: 4755.51 g/mol
Classification: GIP / GLP-1 / glucagon triple receptor agonist.
Research classification: Metabolic research / peptide pharmacology / receptor signalling.

FAQ's & Tips

What is Retatrutide?
Retatrutide is an experimental synthetic peptide studied as a GIP, GLP-1 and glucagon triple receptor agonist.

What is the reference strength?
30mg.

What is Retatrutide researched for?
Research includes metabolic signalling, GIP and GLP-1 pathways, glucagon signalling, glucose metabolism and energy-balance research.

How is it supplied?
Lyophilised peptide powder for laboratory research.

What variants are available?
10mg, 20mg, 30mg and 40mg.

Is Retatrutide intended for human use?
No. This product is supplied strictly for laboratory and scientific research.

Research

Retatrutide is an investigational, once-weekly peptide that activates the GIP, GLP-1 and glucagon receptors. Research has focused on how simultaneous activity at these three pathways influences glucose regulation, appetite-related signalling, energy balance and body-weight outcomes. Human phase 2 studies have demonstrated biological activity, but retatrutide remains an investigational compound and is not established as a general-purpose treatment. For laboratory research use only.

Reviews